Eugia US LLC is recalling 10,080 vials of Methylprednisolone acetate Injectable Suspension, USP, 400mg per 5mL (80mg/mL). This medication, a corticosteroid used to treat various inflammatory conditions, was found to fail dissolution specifications, meaning the drug may not release into the body as intended. If you or a patient have concerns about health outcomes after receiving this medication, please contact a healthcare provider or pharmacist. Healthcare facilities should immediately stop using the medication and arrange for its return through the manufacturer.
The failure to meet dissolution specifications means the drug may not be absorbed properly by the body, which can lead to reduced effectiveness of the medical treatment. There are no reports of injuries in the provided data, but reduced drug efficacy can impact patient health outcomes.
Manufacturer-coordinated return
Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.